Literature DB >> 1581902

Relationship of VP-16 to the classical multidrug resistance phenotype.

M Sehested1, E Friche, P B Jensen, E J Demant.   

Abstract

The classical multidrug resistance (MDR) phenotype is characterized by cross-resistance between a number of chemically unrelated drugs due to an increased efflux across the plasma membrane via a P-glycoprotein-mediated mechanism. The epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) are usually included among the drugs recognized by this MDR phenotype, and the MDR EHR2/DNR cell line is greater than 50-fold cross-resistant to VP-16. The steady-state accumulation of VP-16 in EHR2/DNR cells is only half that of wild-type EHR2 cells, and deprivation of energy by sodium azide surprisingly increased accumulation to a similar extent in both sublines. Efflux was rapid (halflife of 32-35 s) and similar in both sublines, while initial influx was markedly lower in the resistant cells. The temperature coefficients over 10 degrees C for VP-16 in- and efflux indicated passive transport in both sublines. In agreement with this finding, up to 10-fold molar excess (50 microM) VM-26 had no effect on VP-16 accumulation in MDR cells. VP-16 at a 100-fold molar excess inhibited azidopine photoaffinity labeling of P-glycoprotein by only 30% and vincristine binding to plasma membrane vesicles from EHR/DNR cells by 45%. However, VP-16 itself did not differentially bind to plasma membrane vesicles from EHR2 and EHR2/DNR cells. Finally, neither VP-16 accumulation nor cytotoxicity in EHR2/DNR cells were increased to the same degree as for daunorubicin and vincristine by verapamil, and the modulation was similar in wild-type and resistant cells. Thus, although VP-16 may be a substrate for P-glycoprotein, its other transport characteristics such as rapid diffusion and sensitivity to membrane perturbation in wild-type cells lessen any effect of P-glycoprotein-mediated efflux, resulting in a lack of differential modulation by verapamil. These results may be considered when planning clinical trials involving MDR modulators and epipodophyllotoxin derivatives.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1581902

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance.

Authors:  B T Hill; L K Hosking
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.

Authors:  B L Leu; J D Huang
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

Review 4.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 5.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 6.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 7.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

8.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

Authors:  P B Jensen; I J Christensen; M Sehested; H H Hansen; L Vindeløv
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

9.  Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles.

Authors:  D W Loe; F J Sharom
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

10.  An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.

Authors:  L A Doyle; D D Ross; J V Ordonez; W Yang; Y Gao; Y Tong; C P Belani; J C Gutheil
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.